Hello, and welcome back to The Kable, a fairly light one today.
Vaxxas, which most recently won a grant from CEPI for its needle-free vaccine tech, has begun Phase 1 trials of its influenza vaccine in Australia.
India's Biocon, which received a CRL from the US FDA for its Avastin insulin biosimilar last month, now sees its application rejected by the agenβ¦



